

# Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)

メタデータ	<p>言語:</p> <p>出版者: 東京女子医科大学学会</p> <p>公開日: 2024-01-12</p> <p>キーワード (Ja):</p> <p>キーワード (En):</p> <p>作成者: BABAZONO, Tetsuya, MURATA, Hidekazu, SATO, Manaka, TAKEUCHI, Masakazu</p> <p>メールアドレス:</p> <p>所属:</p>
URL	<a href="http://hdl.handle.net/10470/0002000052">http://hdl.handle.net/10470/0002000052</a>

**Supplementary Table 2.** Demographics, clinical characteristics, and diabetes medications in subgroups based on body mass index, glycated hemoglobin, and insulin use.

Variable	BMI subgroup				HbA1c subgroup				Insulin use subgroup		
	<25 kg/m <sup>2</sup> (n = 11)	25 to <30 kg/m <sup>2</sup> (n = 31)	≥30 kg/m <sup>2</sup> (n = 38)	P-value	<8% (n = 20)	8% to <10% (n = 45)	≥10% (n = 15)	P-value	Insulin users (n = 28)	Insulin non-users (n = 52)	P-value
Age (years)	58.6 ± 9.6	55.1 ± 9.5	50.4 ± 10.7	0.03	52.8 ± 8.3	53.0 ± 11.4	55.2 ± 10.5	0.76	54.5 ± 8.0	52.7 ± 11.6	0.42
Male sex	8 (72.7)	17 (54.8)	25 (65.8)	0.40	13 (65.0)	25 (55.6)	12 (80.0)	0.44	18 (64.3)	32 (61.5)	0.73
Duration of diabetes (years)	12.9 ± 6.5	13.7 ± 9.0	13.6 ± 8.4	0.96	10.3 ± 6.2	14.1 ± 8.4	16.2 ± 9.7	0.09	17.2 ± 8.6	11.6 ± 7.6	0.005
Time from SGLT2i initiation to GLP-1RA initiation (days)	451 ± 310	679 ± 478	668 ± 521	0.37	605 ± 521	693 ± 485	540 ± 424	0.53	573 ± 404	680 ± 518	0.31
BMI (kg/m <sup>2</sup> )	22.5 ± 1.6	28.3 ± 1.2	34.9 ± 4.1	<0.001	30.6 ± 5.4	30.3 ± 5.5	31.8 ± 4.9	0.67	31.9 ± 5.1	30.0 ± 5.4	0.12
Body weight (kg)	65.8 ± 5.1	77.0 ± 7.6	98.0 ± 15.6	<0.001	85.1 ± 21.8	84.2 ± 16.7	89.5 ± 11.2	0.59	88.5 ± 17.3	83.7 ± 17.1	0.24
HbA1c (%)	9.0 ± 2.2	8.7 ± 1.1	9.1 ± 1.8	0.54	7.3 ± 0.5	8.8 ± 0.5	11.5 (1.7)	<0.001	9.5 ± 2.1	8.6 ± 1.3	0.048
SBP (mmHg)	127.0 ± 21.5	131.3 ± 13.3	133.6 ± 16.1	0.55	136.2 ± 14.6	133.1 ± 16.7	123.5 ± 11.9	0.08	131.9 ± 14.7	132.0 ± 16.6	0.98
	[n = 8]	[n = 24]	[n = 35]		[n = 16]	[n = 38]	[n = 13]		[n = 25]	[n = 42]	
DBP (mmHg)	77.8 ± 9.1	75.4 ± 9.0	80.6 ± 10.0	0.13	80.3 ± 11.2	77.6 ± 9.7	78.5 ± 8.1	0.65	76.4 ± 8.6	79.6 ± 10.2	0.17
	[n = 8]	[n = 24]	[n = 35]		[n = 16]	[n = 38]	[n = 13]		[n = 25]	[n = 42]	
Number of OADs	1.8 ± 1.1	2.0 ± 1.0	2.2 ± 1.0	0.44	1.9 ± 0.9	2.2 ± 1.1	2.2 ± 0.9	0.51			
GLP-1RA				0.51				0.14			0.23
Dulaglutide	8 (72.7)	21 (67.7)	24 (63.2)		12 (60.0)	29 (64.4)	12 (80.0)		18 (64.3)	35 (67.3)	
Liraglutide	3 (27.3)	7 (22.6)	13 (34.2)		5 (25.0)	15 (33.3)	3 (20.0)		10 (35.7)	13 (25.0)	
Exenatide	0 (0.0)	3 (9.7)	1 (2.6)		3 (15.0)	1 (2.2)	0 (0.0)		0 (0.0)	4 (7.7)	
Concomitant diabetes medications											
SGLT2i				0.23				0.60			0.45
Canagliflozin	2 (18.2)	1 (3.2)	5 (13.2)		1 (5.0)	5 (11.1)	2 (13.3)		3 (10.7)	5 (9.6)	
Dapagliflozin	1 (9.1)	4 (12.9)	9 (23.7)		6 (30.0)	6 (13.3)	2 (13.3)		8 (28.6)	6 (11.5)	
Empagliflozin	2 (18.2)	9 (29.0)	3 (7.9)		5 (25.0)	6 (13.3)	3 (20.0)		3 (10.7)	11 (21.2)	
Ipragliflozin	5 (45.5)	14 (45.2)	17 (44.7)		8 (40.0)	21 (46.7)	7 (46.7)		11 (39.3)	25 (48.1)	
Luseogliflozin	1 (9.1)	1 (3.2)	0 (0.0)		0 (0.0)	2 (4.4)	0 (0.0)		1 (3.6)	1 (1.9)	
Tofogliflozin	0 (0.0)	2 (6.5)	4 (10.5)		0 (0.0)	5 (11.1)	1 (6.7)		2 (7.1)	4 (7.7)	
Biguanide	6 (54.5)	22 (71.0)	29 (76.3)	0.37	16 (80.0)	30 (66.7)	11 (73.3)	0.54	17 (60.7)	40 (76.9)	0.13
Sulfonylurea	4 (36.4)	17 (54.8)	14 (36.8)	0.28	6 (30.0)	21 (46.7)	8 (53.3)	0.32	6 (21.4)	29 (55.8)	0.003
Thiazolidinedione	2 (18.2)	6 (19.4)	8 (21.1)	0.97	7 (35.0)	8 (17.8)	1 (6.7)	0.10	7 (25.0)	9 (17.3)	0.41
α-glucosidase inhibitor	4 (36.4)	4 (12.9)	5 (13.2)	0.15	2 (10.0)	9 (20.0)	2 (13.3)	0.57	5 (17.9)	8 (15.4)	0.77
Glinide	0 (0.0)	0 (0.0)	1 (2.6)	0.57	1 (5.0)	0 (0.0)	0 (0.0)	0.22	0 (0.0)	1 (1.9)	0.46
Insulin	2 (18.2)	8 (25.8)	18 (47.4)	0.08	5 (25.0)	16 (35.6)	7 (46.7)	0.41	28 (100)	0 (0.0)	-

Data are mean ± standard deviation or n (%).

BMI, body mass index; DBP, diastolic blood pressure; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; OAD, oral antidiabetic drug; SBP, systolic blood pressure; SGLT2i, sodium-glucose cotransporter 2 inhibitor.